Latest Breaking News On - Alexandra nisipeanu - Page 1 : comparemela.com

Myth versus reality Five misconceptions about background checks in business

Myth versus reality Five misconceptions about background checks in business
nineoclock.ro - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nineoclock.ro Daily Mail and Mail on Sunday newspapers.

Alexandra nisipeanuAlina badeaForensic servicesAlexandru naeSenior managerSenior associateFinancial advisoryDeloitte romania

Occupational fraud generates annual losses of several USD trillion globally How can companies mitigate reputational risks while hiring? - Nine O Clock - first exclusively daily publication to appear in English language in Romania

Opinion article by Alexandru Nae, Senior Manager, Financial Advisory, and Alexandra Nisipeanu, Senior Associate, Financial Advisory, Deloitte Romania From professional background to culture fit, there are a lot of boxes to be checked during the recruitment process, in order to spot the right candidate for a certain role. However, one of the most important steps

Alexandra nisipeanuAssociation of certified fraud examinersGlobal fraudAlexandru naeSenior managerFinancial advisorySenior associateCertified fraud examinersGeneral inspectorate

Janssen: New Subgroup Analysis of the Phase 3 OPTIMUM Study Demonstrates the Benefits of PONVORYTM? (ponesimod) Over teriflunomide in Early Disease Multiple Sclerosis

Early treatment in multiple sclerosis (MS) with higher-potency therapies can improve long-term patient outcomes1,2 New subgroup analysis of the pivotal Phase 3 OPTIMUM trial shows that MS patients

Janssen cilag gmAlexandra nisipeanuJennifer mcintyrePrinzj ponesimodJanssen cilag internationalNone of the janssen pharmaceutical companiesEuropean commissionNational multiple sclerosis societyJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonActelion pharmaceuticals ltdExchange commissionJanssen global servicesCompanies of johnsonIdorsia pharmaceuticals ltdEuropean committee

Janssen: European Commission approves PONVORYTM ? (ponesimod), a Once Daily, Oral Therapy for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features

(0) The pivotal Phase 3 OPTIMUM trial showed treatment with ponesimod led to a 30.5 percent reduction in annual relapse rate (p1 The OPTIMUM trial is the first of its kind to compare head-to-head two oral disease modifying treatments (DMTs) in RMS Approval follows more than 10 years of cumulative data from Phase 2 and Phase 3 studies demonstrating ponesimod s efficacy and safety 1,2,3 Approval builds on Janssen s deep-rooted history in neuroscience and reinforces Company commitment to addressing unmet needs for neurological conditions like MS Janssen, the Pharmaceutical Companies of Johnson Johnson, announced today that the European Commission (EC) has approved PONVORY ? (ponesimod) for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

United statesAlexandra nisipeanuGavin giovannoniJennifer mcintyrePrinzj ponesimodChris deloreficeNone of the janssen pharmaceutical companiesEuropean commissionAmericas committee for treatmentSclerosis association of americaNational multiple sclerosis societyJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonActelion pharmaceuticals ltdExchange commission

Janssen Pharmaceutica NV: Janssen Announces Treatment with ERLEADA?(apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Janssen Pharmaceutica NV: Janssen Announces Treatment with ERLEADA?(apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer FOR EMEA PHARMACEUTICAL TRADE AND MEDICAL MEDIA ONLY NOT FOR DISTRIBUTION IN BENELUX, SWEDEN AND ITALY Janssen Pharmaceutica NV (Janssen) announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of apalutamide plus androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) when compared to placebo plus ADT. 1 Results will be featured in an oral presentation at the American Society of Clinical Oncology s Genitourinary (ASCO GU) Cancers Symposium, taking place virtually February 11-13, 2021 (Abstract #11; Rapid Abstract Session: Prostate Cancer, February 11 9:30 PM-10:15 PM CET).

United statesAlexandra nisipeanuNoah reymondJennifer mcintyreChristopher deloreficeAxel merseburgerAsia pacificAmerican society of clinical oncologyMonitoring committeeJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonExchange commissionCompanies of johnsonEuropean medicines agencyAmerican societyClinical oncology